Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AVA6103 |
| Synonyms | |
| Therapy Description |
AVA6103 is a peptide-drug conjugate comprising a peptide moiety bound to exatecan by a FAP-cleavable linker, which releases exatecan in the tumor microenvironment and potentially inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 3139). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AVA6103 | AVA-6103|AVA 6103 | AVA6103 is a peptide-drug conjugate comprising a peptide moiety bound to exatecan by a FAP-cleavable linker, which releases exatecan in the tumor microenvironment and potentially inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 3139). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07454642 | Phase I | AVA6103 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors | Recruiting | USA | 0 |